ERBB2 and breast cancer: The national medical insurance of China now includes the application of pyrotinib combined with a trastuzumab and docetaxel (PyHT) regimen for advanced first-line treatment, providing a more appropriate treatment option for patients with advanced BC and further consolidating the position of pyrotinib in the treatment of HER2-positive advanced BC.